Back Home About Us

National Gay Men's HIV/AIDS Awareness Day: Half Untreated, Most Unaware of PrEP

Only 50% of gay and bi men diagnosed with HIV have started antiretroviral treatment and 42% have achieved undetectable viral load, according to a new Centers for Disease Control and Prevention (CDC) report released ahead of National Gay Men’s HIV/AIDS Awareness Day on September 27. A related survey from the Kaiser Family Foundation found that while gay and bi men see HIV as a top health issue, a majority do not get tested regularly and most do not know about pre-exposure prophylaxis, or PrEP.

alt

Read more:

FDA Approves Elvitegravir and Cobicistat Booster as Stand-alone Drugs

The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences next-generation HIV integrase inhibitor elvitegravir (brand name Viteka) and pharmacoenhancer cobicistat (Tybost) as stand-alone agents to be used in combination antiretroviral therapy. The 2 drugs were already available as part of the Stribild single-tablet regimen.

alt

Read more:

ICAAC 2014: Stribild Works Well Regardless of Age, Sex, or Race/Ethnicity

The elvitegravir-based Stribild single-tablet regimen demonstrated good long-term efficacy and tolerability -- including fewer neuropsychiatric side effects than Atripla -- with consistent results across demographic subgroups, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this month in Washington, DC. Other studies showed that Stribild is a good option for black patients either initiating or switching antiretroviral therapy (ART).

alt

Read more:

Tenofovir Alafenamide Pill Matches Stribild, Gilead Will Seek Approval Soon

A new single-tablet regimen containing tenofovir alafenamide (TAF), elvitegravir, cobicistat, and emtricitabine worked as well as Stribild at 48 weeks in a pair of Phase 3 trials, but had less detrimental effects on the kidneys and bones, Gilead Sciences announced this week. These findings set the stage for evaluation by the U.S. Food and Drug Administration and European regulators.

alt

Read more:

PrEP Rally: As Numbers Rise, Advocates Want Wider Access

The number of people using pre-exposure prophylaxis, or PrEP, to prevent HIV infection has risen steadily over the past year, according to data presented this week at a San Francisco community engagement forum. But PrEP advocates -- including 3 city supervisors -- say more needs to be done to overcome barriers to access for all who want it.

alt

Read more:

More iPrEx and OLE Data Published: Adherence Higher in U.S.

Participants enrolled at the U.S. study sites of the global iPrEx trial of Truvada pre-exposure prophylaxis (PrEP) achieved better adherence than those in other countries, reaching 90% in San Francisco, researchers reported in the September 16 advance edition of Journal of Acquired Immune Deficiency Syndromes. Findings from the iPrEx open-label extension (OLE) were also recently published.

alt

Read more:

ICAAC 2014: Cobicistat Long-term Efficacy Matches Ritonavir as PI Booster

Long-term rates of viral suppression and side effects were similar among people using cobicistat and those using ritonavir as a booster for atazanavir (Reyataz), according to 3-year data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC. Another study found that cobicistat was well-tolerated by people with mild-to-moderate kidney impairment.

alt

Read more:

Many HIV Infections Among Gay Men May Be Related to Condom Failure

About half of all new HIV infections among men who have sex with men in Canada may occur during anal sex with a condom, suggesting that condom failure is more common than previously recognized, according to a report in the September 11 edition of PLoS ONE.

alt

Read more:

ICAAC 2014: Tenofovir Vaginal Ring and Nanoparticle Gel Are Protective in Animal Studies

A vaginal ring that dispenses tenofovir protected all 6 macaque monkeys exposed to an HIV-like virus, while a heat-sensitive vaginal gel containing tenofovir nanoparticles prevented infection of mice, researchers reported at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy last week in Washington, DC.

alt

Read more: